Skip to main content
Loading

Opening Address & Keynote Presentation: The truth about antibodies and polyspecificity

28 Oct 2024
Antibody Drug Conjugates , Lead Identification & Optimization , Formats & Scaffolds , Bi/Multispecifics
Opening Address & Keynote Presentation: The truth about antibodies and polyspecificity

Off-target binding is a significant hurdle in the development of antibody-based therapies, contributing to both drug attrition and adverse events in patients. Recent analysis from our own work identified a surprisingly high off-target rate across the industry, with up to one third of antibody drugs displaying off-target binding. In this presentation, we will discuss the emergence of cell-based protein arrays, including the Membrane Proteome Array, as an alternative and improved technology to assess antibody specificity.

Industry Experts
Rachel Fong, Director of Strategic Partnerships, Membrane Proteome Array - Integral Molecular